NOVARTIS
Updates & Highlights
Novartis: Scaling Breakthroughs to Reach Patients Worldwide
Novartis: Scaling Breakthroughs to Reach Patients Worldwide
Supply Chain Digital · about 1 hour ago
Novartis: Scaling Breakthroughs to Reach Patients Worldwide
Novartis: Scaling Breakthroughs to Reach Patients Worldwide
Supply Chain Digital · about 2 hours ago
Assessing Novartis (SWX:NOVN) Valuation After A Strong Year Of Total Shareholder Returns
Assessing Novartis (SWX:NOVN) Valuation After A Strong Year Of Total Shareholder Returns
Yahoo Finance · about 6 hours ago
Recent Openings
View all 2 jobsAll Jobs
Culture & Mission
Benefits & Perks
Health Insurance
Medical, dental & vision
Remote Work
Work from anywhere flexibility
Learning Budget
Professional development
401(k) Match
Retirement savings
Competitive Salary
Market-rate compensation
Equity/Stock Options
Ownership in the company
Tech Stack
Core Values
Innovation
Pushing boundaries in AI/ML technology
Collaboration
Working together to achieve more
Excellence
Striving for the highest quality
Impact
Making a difference in the world
Office Locations
Team
Are you on the team at Novartis?
Claim this company page to verify ownership, edit details, and respond to applicants.
Claim this company →News & Press
20 recentNovartis: Scaling Breakthroughs to Reach Patients Worldwide
Novartis: Scaling Breakthroughs to Reach Patients Worldwide
Supply Chain Digital · about 1 hour ago
Novartis: Scaling Breakthroughs to Reach Patients Worldwide
Novartis: Scaling Breakthroughs to Reach Patients Worldwide
Supply Chain Digital · about 2 hours ago
Assessing Novartis (SWX:NOVN) Valuation After A Strong Year Of Total Shareholder Returns
Assessing Novartis (SWX:NOVN) Valuation After A Strong Year Of Total Shareholder Returns
Yahoo Finance · about 6 hours ago
Novartis, AbbVie Lose Bid To Halt Wash. 340B Pharmacy Law
Novartis, AbbVie Lose Bid To Halt Wash. 340B Pharmacy Law
Law360 · about 8 hours ago
Novartis and Taiwan Advance a New ASCVD Framework
Novartis and Taiwan Advance a New ASCVD Framework
Taiwan Business TOPICS · about 9 hours ago
NOVARTIS AG : Deutsche Bank remains its Buy rating
NOVARTIS AG : Deutsche Bank remains its Buy rating
marketscreener.com · 1 day ago
Novartis to present Rhapsido data at allergy congress
Novartis to present Rhapsido data at allergy congress
StreetInsider · 2 days ago
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026
GlobeNewswire · 2 days ago
Assessing Novartis (SWX:NOVN) Valuation After Positive Late Stage Results For Cosentyx And Vanrafia
Assessing Novartis (SWX:NOVN) Valuation After Positive Late Stage Results For Cosentyx And Vanrafia
simplywall.st · 2 days ago
How Investors May Respond To Novartis (SWX:NOVN) Expanding Cosentyx And Vanrafia Into Specialty Immune Diseases
How Investors May Respond To Novartis (SWX:NOVN) Expanding Cosentyx And Vanrafia Into Specialty Immune Diseases
simplywall.st · 4 days ago
Novartis (NVS) Reports New Cosentyx® Data in Polymyalgia Rheumatica
Novartis (NVS) Reports New Cosentyx® Data in Polymyalgia Rheumatica
Insider Monkey · 5 days ago
Novartis (NVS) Reports New Cosentyx® Data in Polymyalgia Rheumatica
Novartis (NVS) Reports New Cosentyx® Data in Polymyalgia Rheumatica
Yahoo Finance · 5 days ago
Argus Research Initiates Novartis AG(NVS.US) With Buy Rating, Announces Target Price $160
Argus Research Initiates Novartis AG(NVS.US) With Buy Rating, Announces Target Price $160
富途牛牛 · 5 days ago
Argus Research Initiates Novartis AG(NVS.US) With Buy Rating, Announces Target Price $160
Argus Research Initiates Novartis AG(NVS.US) With Buy Rating, Announces Target Price $160
Moomoo · 5 days ago
Novartis’ heartfelt animation
Novartis’ heartfelt animation
shots.net · 5 days ago
Novartis reports positive results from Phase III ALIGN trial for IgAN
Novartis reports positive results from Phase III ALIGN trial for IgAN
Clinical Trials Arena · 5 days ago
Novartis reports positive results from Phase III ALIGN trial for IgAN
Novartis reports positive results from Phase III ALIGN trial for IgAN
Yahoo · 5 days ago
EULAR: Novartis Closes In On Final Approval For Cosentyx
EULAR: Novartis Closes In On Final Approval For Cosentyx
Citeline News & Insights · 5 days ago
Novartis AG Stock (NVS) Closed Up by 3.12% on Jun 4: A Full Analysis
Novartis AG Stock (NVS) Closed Up by 3.12% on Jun 4: A Full Analysis
TradingKey · 6 days ago
Novartis (NVS) Shows Promising Phase III ALIGN Study Results for Kidney Treatment
Novartis (NVS) Shows Promising Phase III ALIGN Study Results for Kidney Treatment
GuruFocus · 6 days ago